Boston Molecules (BOM)’s viral service offers high-quality and high-titer viral adeno-associated viruses (AAVs); especially we strive to exceed our clients’ expectations on every project while ensuring the highest product quality possible.
BOM distributes AAV as 100 µL or 1 ml solutions of purified viral particles that are suitable for in vivo use. Minimum titers are showed on each item’s material page, and actual titers are reported with each shipment.
- By Function: Chemogenetics, Optogenetics, Recombinases, Biosensors, controls, Molecular Tools, Monosynaptic Neuronal Tracing
- By Serotype: AAV1, 2, 5, 6, 8, 9
Viral Service Information
- Viral Production: Our production process and quality control, with examples of quality control data.
- Ordering Instructions: Shipping, pricing, and payment information.
- Protocols: Written protocols for how to use your virus.
- Recipient Instructions: What to do when you receive your virus from BOM, with details about storage.
- Viral Service Q & A: Answers to commonly asked questions like.
- Biosafety Guide: Documentation for your institutional biosafety office and your lab, information on biosafety features viral vectors, and general biosafety guidelines.
- BOM Blog: Viral Vector Posts: Content from BOM and scientists across the research community on various aspects of viral vectors, including troubleshooting advice and explanations of viral vector technologies.
Adeno-associated viruses (AAV) are small viruses (20 nm) that naturally infect humans and some other primate species, and these viruses are replication – defective, noneveloped with linear single-stranded DNA (ssDNA) genome of approximately 4.8 kilobases (kb).
AAV are not currently known to cause disease, except for a very mild immune response. There are several additional features that make AAV an attractive candidate for creating viral vectors for gene therapy including that AAVs are able to infect both dividing and quiescent cells and persist in an extra-chromosomal state without integrating into the genome of the host cell. A recent approval by the United States Food and Drug Administration for application of AAV to treat a genetic retinal disease has shown promising for gene therapy.
AAV, which had been previously considered as a contaminant in adenovirus preparations, were first identified as dependoparvoviruses in the 1960s in the laboratories of Bob Atchison at Pittsburgh and Wallace Rowe at the United States National Institutes of Health (NIH).
The inverted terminal repeat (ITR) sequences in the two ends of the AAV genome comprise 145 bases each, which was shown to be required for efficient multiplication of the AAV genome as well as for efficient encapsidation of the AAV DNA combined with the generation of a fully assembled, deoxyribonuclease-resistant AAV particles.
For gene therapy, ITRs are required for the therapeutic gene as structural (cap) and packaging (rep) proteins can be delivered in trans. However, it was also reported that the ITRs are not the only elements required in cis for the effective replication and encapsidation because a sequence designated cis-acting Rep-dependent element (CARE) inside the coding sequence of the rep gene was shown to augment the replication and encapsidation when present in cis.
AAV Service Quotation Request Form
Our customer representatives are available 24/7/365 to assist you. Order By
- Email: [email protected]
- Phone: 617-651-1016
- Fax: 617-651-1016